Skip to main content

Table 4 Data Inputs and distribution in Markov model

From: Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis

Variable Mean/Mode Distribution Source
Probabilities    
Probabilities of non-symptomatic to stroke or CHD See Table 2 Gamma 6
Probability from stroke to Death 0.27 Beta (α 0.27, β 0.73) 29
Probability from CHD to Death 0.51 Beta (α 0.49, β 0.51) 29
Relative Risk    
Relative Risk of Thiazide to Stroke 0.63 Normal (α 0.63, se 0.056) 4
Relative Risk of Thiazide to CHD 0.84 Normal (α 0.84, se 0.060) 4
Relative Risk of Thiazide to Death 0.89 Normal (α 0.89, se 0.037) 4
Relative Risk of Propranolol to Stroke 0.83 Normal (α 0.83, se 0.076) 4
Relative Risk of Propranolol to CHD 0.90 Normal (α 0.90, se 0.071) 4
Relative Risk of Propranolol to Death 0.96 Normal (α 0.96, se 0.056) 4
Relative Risk of Lisinopril to Stroke 0.65 Normal (α 0.65, se 0.116) 4
Relative Risk of Lisinopril to CHD 0.81 Normal (α 0.81, se 0.075) 4
Relative Risk of Lisinopril to Death 0.83 Normal (α 0.83, se 0.071) 4
Relative Risk of Nifedipine to Stroke 0.58 Normal (α 0.58, se 0.183) 4
Relative Risk of Nifedipine to CHD 0.77 Normal (α 0.77, se 0.174) 4
Relative Risk of Nifedipine to Death 0.86 Normal (α 0.86, se 0.120) 4
Resources (Annual cost/patient in US Dollars)    
Thiazide 89.69 Triangular (min 71.75, max 107.63) 11
Propranolol 103.36 Triangular (min 82.69, max 124.03) 11
Lisinopril 404.08 Triangular (min 323.26, max 484.89) 11
Nifedipine 294.72 Triangular (min 235.78, max 353.67) 11
Hospitalization cost for Stroke 873.62 Triangular (min 698.89, max 1048.34) 11,12,UNTH
Hospitalization cost for CHD 311.73 Triangular (min 249.39, max 374.08) 11, UNTH
Management of Stroke and CHD Patients 417.74 Triangular (min 334.20, max 501.29) 11
Health Utilities    
Hypertensive patients 0.57 Beta (α 206.1, β 155.1) Unpublished
Stroke Patients 0.04 Beta (α 1.0, β 23.3) Unpublished
CHD 0.13 Beta (α 4.9, β 32.9) Unpublished
Discount Rate    
Cost and Utility 3% Triangular (min 0%, max 5%) 30